Actuate Therapeutics, Inc. Research and Development Expense
Actuate Therapeutics, Inc. (ACTU) reported Research and Development Expense of $2.07 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-14
- Actuate Therapeutics, Inc. research and development expense for the quarter ending 2026-06-30 was $2.07M, a 25.25% decline year-over-year.
- Actuate Therapeutics, Inc. research and development expense for the quarter ending 2026-03-31 was $2.57M, a 20.34% decline year-over-year.
- Actuate Therapeutics, Inc. research and development expense for the quarter ending 2025-12-31 was $2.13M, a 42.22% decline year-over-year.
- Actuate Therapeutics, Inc. research and development expense for the quarter ending 2025-09-30 was $2.18M, a 42.03% decline year-over-year.
- Actuate Therapeutics, Inc. research and development expense for fiscal 2025 was $10.29M, a 44.89% decline from fiscal 2024.
- Actuate Therapeutics, Inc. research and development expense for fiscal 2024 was $18.68M, a 13.97% decline from fiscal 2023.
- Actuate Therapeutics, Inc. research and development expense for fiscal 2023 was $21.71M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.07M 10-Q · filed 2026-08-14 | $4.63M 10-Q · filed 2026-08-14 | $6.76M derived: sum of 3 quarters · filed 2026-08-14 | $8.94M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $2.57M 10-Q · filed 2026-05-14 | $4.69M derived: sum of 2 quarters · filed 2026-05-14 | $6.87M derived: sum of 3 quarters · filed 2026-05-14 | $9.64M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $2.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $4.31M derived: sum of 2 quarters · filed 2026-03-26 | $7.07M derived: sum of 3 quarters · filed 2026-08-14 | $10.29M 10-K · filed 2026-03-26 |
| 2025-09-30 | $2.18M 10-Q · filed 2025-11-13 | $4.94M derived: sum of 2 quarters · filed 2026-08-14 | $8.16M 10-Q · filed 2025-11-13 | $11.85M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $2.76M 10-Q · filed 2026-08-14 | $5.99M 10-Q · filed 2026-08-14 | $9.67M derived: sum of 3 quarters · filed 2026-08-14 | $13.43M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $3.22M 10-Q · filed 2026-05-14 | $6.91M derived: sum of 2 quarters · filed 2026-05-14 | $10.66M derived: sum of 3 quarters · filed 2026-05-14 | $15.04M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $3.69M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $7.44M derived: sum of 2 quarters · filed 2026-03-26 | $11.82M derived: sum of 3 quarters · filed 2026-03-26 | $18.68M 10-K · filed 2026-03-26 |
| 2024-09-30 | $3.76M 10-Q · filed 2025-11-13 | $8.13M derived: sum of 2 quarters · filed 2025-11-13 | $14.99M 10-Q · filed 2025-11-13 | $21.64M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $4.37M 10-Q · filed 2025-08-14 | $11.23M 10-Q · filed 2025-08-14 | $17.88M derived: sum of 3 quarters · filed 2025-08-14 | $23.64M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $6.86M 10-Q · filed 2025-05-15 | $13.51M derived: sum of 2 quarters · filed 2025-05-15 | $19.27M derived: sum of 3 quarters · filed 2025-05-15 | $24.05M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $6.65M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $12.41M derived: sum of 2 quarters · filed 2025-03-13 | $17.18M derived: sum of 3 quarters · filed 2025-03-13 | $21.71M 10-K · filed 2025-03-13 |
| 2023-09-30 | $5.76M 10-Q · filed 2024-11-13 | $10.54M derived: sum of 2 quarters · filed 2024-11-13 | $15.06M 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $4.78M 10-Q · filed 2024-09-24 | $9.30M 10-Q · filed 2024-09-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B |